Bristol Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,296,000. Gilead Sciences comprises approximately 1.3% of Bristol Advisors LLC’s portfolio, making the stock its 18th largest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences in the 2nd quarter valued at about $147,000. Hanson & Doremus Investment Management lifted its holdings in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $172,000. 76.11% of the stock is currently owned by hedge funds and other institutional investors.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the sale, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold 591,666 shares of company stock worth $44,466,567 over the last 90 days. 1.30% of the stock is currently owned by company insiders.

Shares of Gilead Sciences, Inc. (GILD) opened at $88.80 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54. The firm has a market cap of $115,970.00, a P/E ratio of 10.10, a PEG ratio of -1.89 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period last year, the business posted $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

GILD has been the topic of several recent analyst reports. Jefferies Group reiterated a “hold” rating and set a $93.00 price objective on shares of Gilead Sciences in a report on Wednesday, October 4th. Bank of America cut their price objective on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday, October 4th. Oppenheimer initiated coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They set a “market perform” rating on the stock. CIBC started coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They set a “market perform” rating on the stock. Finally, Leerink Swann raised their price target on shares of Gilead Sciences from $87.00 to $89.00 and gave the company a “market perform” rating in a report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $85.58.

COPYRIGHT VIOLATION NOTICE: “Bristol Advisors LLC Acquires Shares of 16,000 Gilead Sciences, Inc. (GILD)” was first published by Marea Informative and is owned by of Marea Informative. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.mareainformativa.com/bristol-advisors-llc-takes-1-30-million-position-in-gilead-sciences-inc-gild-updated-updated-updated/125996/.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.